A technology to save lives IV PREV: PREVENTING INFECTIONS Kanika Bansal Founder Medicen Devise Limited Presented to Gabriel 19 th September,

Infections due to catheters 1 in 4 infected patients die Antibiotic resistance $6Billion treatment cost 2 2

Existing Solutions Following precautions as per guidelines Antiseptic coated catheter Antiseptic coated dressing 3 3

Issues with Existing Solution Asphyxiation Irregular Dry up quickly No Warning 4

Our Solution: IV Prev Externally attached to catheter Automatically sterilizes area reducing 99.9% skin bacteria End-User Feedback: Addenbrookes, Cambridge & Royal Infirmary, Edinburgh Patent Filed 5

Competitor Analysis ProductsAntiseptic Effect with time Antiseptic Used LifetimeWarning System/Ind ication IV PrevMaintains constant effect Any off the shelf Same as patient stay Yes Coated catheter DecliningSpecific7-10 daysNo Antiseptic Dressings DecliningCHG only2-3 daysNo 6

Initial Target Market for IV Prev20% Market Size for IV Prev Total Addressable Market: 22 Million units in US & Europe/Year Potential of £1.5 Billion revenue/year in US & Europe 7 Source: US Venous Access Catheter Market, 2010 by Frost & Sullivan

Customers Catheter Manufacturers Antiseptic Manufacturers Hospital Procurement CR Bards Covidien Becton Dickinson 3M GSK Systagenix Teleflex Influenced by Hospital Procurement Influenced by KOL 8

Option to consider Sub-contract manufacturing and independent medical device distribution route Route to Market: Licensing Model 9 KOL Feedback Catheter & Antiseptic Manufacturers

Value Proposition for Customer Increased margins by combining anti-infective device with current product Have consumables having recurrent sales Address key market driver in rapidly growing market Global Appeal Short Development cycle 10

Value Proposition for User Benefits to Hospital Procurement Easier reimbursement from Medicaid Less replacement catheters, dressings and antibiotics leading to reduced cost Reduced hospital stay of patient Benefits to End-User Reduction in infections Ease in use No compromise with sterility of catheter 11

CatheterSelling Price of catheter Selling Price of IV Prev Cost saved by IV Prev (If Minimum 10% effective) Cardiology (Central Venous Catheters) PICC£220£44£64 Million CVC£150£30£312 Million Urology Dialysis Catheter £700£140£82 Million Foley Catheter£10 £185 Million Intravenous Ports£1000£200£15 Million Total savings for NHS after removing introduction cost£494 Million Catheter Segmentation 12 Estimated sub-contract manufacturing cost: £2/ device

Action Plan Q4-Q5Q6 Business Model Product Development Completed Q1-Q3 Regulations Conceptualization Proof of Concept Engagement with end user (KOL) Prototyping Initial biology lab Testing CE Mark FDA License to commercial partner Clinical Study for market traction Marketing Customer Engagement £150k£200k£150k 13

Financial Projection 14 Year IV Prev sold 00118k583k1000k Consumables sold 00354k1896k3000k Market Captured 0% 1%5%8% Turnover 00£280,911£2.79M£6.81M Upfront Payment 00£250,00000 Overheads £167,636£181,482£333,665£359,180£384,102 Net Profit/(Loss) (£167,636)(£181,482)£197,246£2.43M£6.43M

Funding (Net Investment) Phase 1: £150k Oct June 2014 SMART Grant (Applied) £100kDevelopment of soft tooling for final prototype manufacturing, testing for CE Mark, filing of CE Mark and FDA application Private Funding£50k Phase 2: £350k July 2014 Private Funding£350Clinical studies and health economic studies for market traction, PCT and national phase patent maintenance & corporate overheads 15

Team Founder Director (Kanika Bansal) MSc Biomechanical Engineering 2 years manufacturing & 5 years of designing experience Advisor/(NXD) (Ian Muirhead) Expertise in medical device start-ups Experienced in raising funds Chairman (To be Appointed) Expertise in clinical studies and marketing of medical products 16

Summary Annually 250,000 cases of infections in US with a cost of $6.25 Billion IV Prev will reduce infections and healthcare associated costs for infections $1.5 Billion market to target for IV Prev Initiating regulatory and customer engagement Next stage will be to conduct clinical evaluation, in parallel will continue customer engagement We need to secure £500,000 funding for product development, clinical studies and patent maintenance & corporate overheads Exit potential through trade sale within 5 years 17